MonumenTAL-1: Talquetamab in Relapsed/Refractory MM
Donna Catamero, ANP-BC, OCN, CCRC, reviews findings from the MonumenTAL-1 study and the panel provides its impressions of the results.
This is a video synopsis/summary of a Between the Lines series featuring Donna Catamero, ANP-BC, OCN, CCRC; Cesar Rodriguez, MD; and Saad Usmani, MD, MBA, FACP.
Results from the phase 1/2 MonumenTAL-1 trial (NCT03399799) led to FDA approval of talquetamab, a GPRC5D-targeting bispecific antibody, for relapsed/refractory multiple myeloma (MM) after at least 3 prior lines including proteasome inhibitors, immunomodulators, and anti-CD38 antibodies. Patients received step-up dosing of talquetamab 0.4 mg/kg weekly, 0.8 mg/kg every other week, or either schedule after prior T-cell redirection therapy. Overall response rates were 72% to 74% (65% after prior therapy), very good partial response or better rate was 65% (55% after prior therapy), median progression-free survival was 5.1 to 14.2 months, and 12-month duration of response rates for complete response were 79% to 90%. Adverse events included cytokine release syndrome, dysgeusia, dermatologic toxicity, and cytopenias. Infection rates were 59% to 73% (higher after prior therapy).
Rodriguez found talquetamab efficacy and durability comparable to BCMA-directed treatments. Usmani welcomed talquetamab while noting the need for sequencing data between GPRC5D and BCMA targets. Limitations include lack of patients with high-risk disease features to inform effectiveness in these groups.
Video synopsis is AI generated and reviewed by CancerNetwork® editorial staff.
The Hidden Danger Unveiling the Connection Between Multiple Myeloma and Pleural Effusion
This case highlights the importance of early recognition and management of pleural effusion in patients with multiple myeloma and underscores the need for further research into optimal management strategies and underlying mechanisms.
